- Home
- RDWR vs PVLA Comparison
RDWR vs PVLA Comparison
Compare RDWR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDWR | PVLA |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | RDWR | PVLA |
|---|---|---|
| Price | $24.23 | $87.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $32.50 | ★ $141.50 |
| AVG Volume (30 Days) | 296.0K | ★ 302.0K |
| Earning Date | 02-11-2026 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $294,636,000.00 | N/A |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | $62.55 | ★ N/A |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $18.46 | $11.28 |
| 52 Week High | $31.57 | $114.69 |
Technical Indicators
Market Signals| Indicator | RDWR | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 43.27 |
| Support Level | $23.53 | $99.18 |
| Resistance Level | $24.46 | $105.54 |
| Average True Range (ATR) | 0.57 | 9.85 |
| MACD | 0.02 | -1.34 |
| Stochastic Oscillator | 62.20 | 17.21 |
Price Performance
Historical ComparisonAbout RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.